| Product Code: ETC6752665 | Publication Date: Sep 2024 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Summon Dutta | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
China rituximab import market continued to show strong growth in 2024, with key exporting countries including the USA, Sweden, Japan, UK, and Canada. The high Herfindahl-Hirschman Index (HHI) indicates a concentrated market, while the impressive Compound Annual Growth Rate (CAGR) of 7.98% from 2020 to 2024 highlights sustained expansion. The growth rate of 11.82% from 2023 to 2024 signals accelerating momentum in the market, suggesting increasing demand for rituximab in China. This data points to a robust and competitive landscape for rituximab imports in the Chinese market.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Rituximab Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Rituximab Market Revenues & Volume, 2021 & 2031F |
3.3 China Rituximab Market - Industry Life Cycle |
3.4 China Rituximab Market - Porter's Five Forces |
3.5 China Rituximab Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.6 China Rituximab Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 China Rituximab Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of autoimmune diseases and cancer, leading to higher demand for rituximab. |
4.2.2 Growing healthcare infrastructure and investments in China, facilitating better access to rituximab treatments. |
4.2.3 Rising healthcare expenditure and insurance coverage, enabling more patients to afford rituximab therapy. |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and approval processes for biologic drugs like rituximab in China. |
4.3.2 Presence of alternative therapies and biosimilar competition impacting market share and pricing. |
5 China Rituximab Market Trends |
6 China Rituximab Market, By Types |
6.1 China Rituximab Market, By Route of Administration |
6.1.1 Overview and Analysis |
6.1.2 China Rituximab Market Revenues & Volume, By Route of Administration, 2021- 2031F |
6.1.3 China Rituximab Market Revenues & Volume, By Subcutaneous, 2021- 2031F |
6.1.4 China Rituximab Market Revenues & Volume, By Intravenous, 2021- 2031F |
6.1.5 China Rituximab Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.2 China Rituximab Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 China Rituximab Market Revenues & Volume, By Non-Hodgkin's Lymphoma, 2021- 2031F |
6.2.3 China Rituximab Market Revenues & Volume, By Chronic Lymphocytic Leukemia, 2021- 2031F |
6.2.4 China Rituximab Market Revenues & Volume, By Rheumatoid Arthritis, 2021- 2031F |
6.2.5 China Rituximab Market Revenues & Volume, By Others, 2021- 2031F |
7 China Rituximab Market Import-Export Trade Statistics |
7.1 China Rituximab Market Export to Major Countries |
7.2 China Rituximab Market Imports from Major Countries |
8 China Rituximab Market Key Performance Indicators |
8.1 Patient adherence rate to rituximab therapy. |
8.2 Number of clinical trials and research studies on rituximab conducted in China. |
8.3 Percentage of rituximab prescriptions filled within a specified time frame. |
8.4 Rate of adverse events reported related to rituximab treatment. |
8.5 Level of physician awareness and education on rituximab indications and usage. |
9 China Rituximab Market - Opportunity Assessment |
9.1 China Rituximab Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.2 China Rituximab Market Opportunity Assessment, By Application, 2021 & 2031F |
10 China Rituximab Market - Competitive Landscape |
10.1 China Rituximab Market Revenue Share, By Companies, 2024 |
10.2 China Rituximab Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |